PATENT CLAIM ANALYSIS

Application Number: 15751901
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "325000"]

Abstract:
The invention provides treating cachexia and eating disorders in humans and veterinary animals by administering a composition including: (i) cyproheptadine (CYP); and (ii) a cannabis compound selected from the group of cannabidiol (CBD) and mixtures of CBD and up to 50% tetrahydrocannabinol (THC).

Claim (Index 8):
Method of  claim 1  wherein the maximum dosage of CYP is about 0.2 mg/day for each kg of patient body weight and the minimum dosage of cannabis compound is about 10 mg/day for each kg of patient body weight.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.35714
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11115983', '16094802', '15789998', '15876219', '10468041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.721950702072711
- 35 USC 102 Novelty (BERT): 0.5022587372473369
- Combined Prediction Score: 0.6999815055901735
- Mean Citation Score: 205.18951
- Max Citation Score: 213.71086
- Similarity Product: 149.3976230801773

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test